74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
R RaySearch Laboratories AB
R
Open
225 0.67
Overview
Share price change
24h
Min
217
Max
226.5
Income | 19M 77M |
|---|---|
Sales | 29M 323M |
P/E Sector Avg | 37.943 63.778 |
EPS | 1.32 |
Dividend yield | 1.3 |
Profit margin | 23.999 |
Employees | 416 |
EBITDA | 12M 74M |
Dividend yield Sector Avg | 1.30% 2.39% |
|---|---|
Next Earnings | 25 Apr 2025 |
Market Cap | -1.1B 7.7B |
|---|---|
Previous open | 224.33 |
Previous close | 225 |
RaySearch Laboratories AB Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
RaySearch Laboratories AB Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About RaySearch Laboratories AB
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer care in the Americas, Europe, Africa, the Asia-Pacific, and the Middle East. It develops and markets RayStation, a treatment planning system for radiation therapy; RayCare, an oncology information system that manages clinical activities; RayIntelligence, a cloud-based analytics system for monitoring and enhancement of cancer therapy; and RayCommand, a treatment control system that serves as link between the treatment machine and the treatment planning and oncology information systems. The company offers RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, and electron beam radiation therapy; and µ-RayStation, a software platform for planning and evaluation in small animal irradiation research. The company (publ) is headquartered in Stockholm, Sweden.
